Suggested remit: To appraise the clinical and cost effectiveness of crisaborole within its marketing authorisation for treating mild to moderate atopic dermatitis in people aged 2 years and older.
Status In progress
Process STA 2018
ID number 1195

Provisional Schedule

Expected publication 03 June 2020

Project Team

Project lead Jeremy Powell

Email enquiries

Evidence Review Group / Assessment Group School of Health and Related Research (ScHARR), University of Sheffield


Companies sponsors Pfizer (crisaborole)
Others Department of Health and Social Care
  NHS England
  NHS Cannock Chase CCG
  NHS South Worcestershire CCG
  Welsh Government
Patient carer groups Action Against Allergy
  Action for Sick Children –
  Allergy UK
  Changing Faces
  Let’s Face it
  Muslim Council of Britain
  National Children’s Bureau
  The National Eczema Society
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups Association of Paediatric Emergency Medicines
  British Association for Accident and Emergency Medicine
  British Association for Immediate Care
  British Association of Dermatologists
  British Contact Dermatitis Society
  British Dermatological Nursing Group
  British Geriatrics Society
  British Society for Cutaneous Allergy -
  British Skin Foundation
  British Trauma Society
  Primary Care Dermatology Society
  Royal College of Emergency Medicine
  Royal College of General Practitioners
  Royal College of Paediatrics & Child Health
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Surgical Dressing Manufacturers Association
  Tissue Viability Society
  UK Clinical Pharmacy Association


Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare (tacrolimus)
  Accord UK (betamethasone valerate, hydrocortisone)
  Alliance Pharmaceuticals (benzalkonium chloride, dimeticone, hydrocortisone, nystatin)
  Aspire Pharma (fluticasone propionate)
  Auden Mckenzie Pharma Division, a subsidiary of Actavis PLC (betamethasone valerate, mometasone furoate)
  Boots Company PLC (hydrocortisone)
  Dermal Laboratories (hydrocortisone)
  Ennogen Healthcare (clobetasone butyrate, nystatin, oxytetracycline calcium)
  Galderma UK (hydrocortisone)
  Generics UK T/A Mylan (betamethasone valerate, mometasone furoate)
  GlaxoSmithKline Consumer Healthcare (betamethasone valerate, clobetasone butyrate, fluticasone propionate, hydrocortisone)
  Glenmark Pharmaceuticals Europe (mometasone furoate)
  Intrapharm Laboratories (hydrocortisone, oxytetracycline hydrochloride)
  Janssen-Cilag (hydrocortisone)
  Karo Pharma AB (hydrocortisone)
  Leo Laboratories (betamethasone valerate, fusidic acid, hydrocortisone, tacrolimus)
  Marlborough Pharmaceuticals (hydrocortisone)
  Merck Sharp & Dohme (betamethasone dipropionate, mometasone furoate)
  Mylan (pimecrolimus)
  Pinewood Healthcare (hydrocortisone)
  Reckitt Benckiser Healthcare (hydrocortisone)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community H
  ealth Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups British Epidermo-Epidemiology Society
  Centre of Evidence-based Dermatology, University of Nottingham
  Cochrane Skin Group
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research
  Skin Research Centre
  Skin Treatment & Research Trust


Key events during the development of the guidance:

Date Update
12 March 2020 Committee meeting: 1
16 July 2019 Invitation to participate
16 June 2019 In progress, Appraisal has been referred to NICE.
20 November 2018 - 18 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance